For information on this past event please contact Meetings Management

Conference Program

Wednesday 19th September 2007

SESSION 8:
SPECIAL SANARIA SESSION

09.00-10.45
‘Plans for developing, testing and fielding a metabolically active, non-replicating whole parasite Plasmodium falciparum sporozoite vaccine’
Moderator: Stephen Hoffman (Sanaria Inc., Rockville, Maryland, USA)

‘Introductory remarks’
John McNeil (PATH Malaria Vaccine Initiative, Bethesda, Maryland, USA)

‘Background, research, process development, manufacturing, release assays and timeline’
Stephen L. Hoffman, Peter Billingsley, Eric James, Kim Lee Sim, Rana Chattopadhyay, Mark Loyevsky, Adam Richman and Lucy Andrews Donkor (Sanaria Inc., Rockville, Maryland, USA)

‘A metabolically active, non-replicating Plasmodium falciparum sporozoite vaccine: The first phase 1/2a clinical trial and beyond’
Judith E. Epstein et al. (NMRC, Silver Spring, Maryland, USA)

10.45-11.15
Coffee & Posters

SESSION 9:
VACCINE CANDIDATES I
Moderator: David E. Lanar (WRAIR, USA)

11.15-11.35
‘Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif’
Giampietro Corradin et al. (University of Lausanne, Switzerland)

11.35-11.55
‘A multi-stage, multi-antigen adenovirus-vectored vaccine against P. falciparum malaria’
D. Regis, M. Sedegah, D.L. Doolan, K. Limbach, J. Bruder, G. Levine, N. Patterson, J. Mendoza-Silveiras, F. Williams, I. Chuang, J. Epstein, M. Reyes, V. Steinbeiss, F. Parekh, C.R. King, D. Carucci, L. Soisson, C. Diggs and T. Richie (NMRC, Silver Spring, Maryland, USA)

11.55-12.15
‘Evaluation of malaria vaccine FMP1/AS02A-induced antibody fine specificities from a pediatric Phase 2b Trial in Western Kenya’
Evelina Angov et al. (WRAIR, Silver Spring, Maryland, USA)

12.15-12.35
‘Progress toward an anti-GPI vaccine for malaria infection: Practical access to the synthetic GPI antigen’
A.S. Campbell, W. Christ, Y. Guo, M. Jones, P. Seeberger and L. Schofield (Ancora Pharmaceuticals Inc., Medford, Massachusetts, USA)

12.35-12.55
‘Antigenic escape residues of apical membrane antigen-1 of Plasmodium falciparum’
S. Dutta, S.Y. Lee, A.H. Batchelor and D.E. Lanar (WRAIR, Silver Spring, Maryland, USA)

12.55-14.00
Lunch & Posters

SESSION 10:
IMMUNE RESPONSE
Moderator: Adrian Hill (University of Oxford, UK)

14.00-14.20
‘Greatly enhanced immune responses from priming with adenovirus35-CS followed by RTS,S/AS01B boost in rhesus macaques’
V. Ann Stewart et al. (WRAIR, Silver Spring, Maryland, USA)

14.20-14.40
‘Genetically-attenuated Plasmodium berghei liver-stage induce sterile protracted protection that is mediated by MHC class-I-dependent IFN-γ producing CD8⁺ T cells’
Urszula Krzych et al. (WRAIR, Silver Spring, Maryland, USA)

14.40-15.00
‘Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies’
J.T. Bruder, E. Semenova, C. Thomas, N.B. Patterson, M.E. Stefaniak, K. Limbach, C. Richter King and D.L. Doolan (GenVec Inc., Gaithersburg, Maryland, USA)

15.00-15.20
Tea & Posters

SESSION 11:
VACCINE CANDIDATES II
Moderator: David E. Lanar (WRAIR, USA)

15.20-15.40
‘Var2CSA products mediate binding to CSA, but can this be the basis of a vaccine against malaria in pregnancy?’
Graham V. Brown, Michael F. Duffy, Stephen J. Rogerson and James G. Beeson (University of Melbourne, Victoria, Australia)

15.40-16.00
‘A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies’
A. Yadava, J. Sattabongkot, M.A. Washington, L.A. Ware, V. Majam, H. Zheng, S. Kumar and C.F. Ockenhouse (WRAIR, Silver Spring, Maryland, USA)

16.00-16.20
‘The rationale design of synthetic peptide vaccines and adjuvants for optimal class II-mediated immune responses to plasmodium pre-erythrocytic stages’
Elizabeth H. Nardin (New York University School of Medicine, New York, USA)

SESSION 12:
CLOSING PLENARY PRESENTATION
Moderator: Eleanor Riley (LSHTM, London, UK)

16.20-16.50
‘Future outlook for malaria vaccines’
Adrian Hill (University of Oxford, UK)

Conference Close & Departure